60 results about "Skeletal disorder" patented technology

The invention belongs to the field of biological products, and particularly relates to a bone glue product for preventing and treating osteoporosis and application, the bone glue comprises sheep bone glue (small molecules), pig bone glue (small molecules) and black pig bone glue (small molecules); five animals are beneficial, sheep and pigs are food beneficial to body health, bones are made into bone glue (small molecules) through modern production processes such as an enzyme preparation method and the like, the bone glue (small molecules) is easily dissolved in water and easily absorbed by a human body, can supplement colloid in the bones, is non-toxic and can be eaten for a long time; due to different yin and yang attributes, different types of osteoporosis patients can be prevented and treated; the traditional Chinese medicine also has good prevention and treatment effects on complications, fracture, hairline fracture, arthralgia and other bone diseases caused by osteoporosis; the compound can be applied to preparation of medicines, foods and health-care foods for preventing and treating osteoporosis.

The invention discloses a long-acting GGG three-target agonist, and the compound provided by the invention simultaneously achieves nM-level excellent agonist ability on three targets of GLP-l / GIP / GCGR, and can fully excite corresponding target organ tissue cells. The compound provided by the invention can promote insulin secretion and reduce blood sugar; in addition, ingestion can be inhibited, gastric emptying can be delayed, energy consumption can be increased, and finally the weight reduction effect can be observed. The compound provided by the invention can reduce pancreatic beta-cell apoptosis, increase the quantity of pancreatic beta-cells and improve functions of pancreatic cells. The compound disclosed by the invention can also improve blood fat, reduce liver fat accumulation and inhibit liver inflammation development. The compound or the composition can be used for preventing and / or treating metabolic disorder diseases and related complications thereof. The compound or the composition can be used for treating bone diseases related to endocrine diseases, metabolic disorders, nephropathy and the like, such as osteoporosis and osteoarthritis.

The present invention relates to a composition comprising 4-hexylresorcinol (4-HR) as an active ingredient for prevention or treatment of a bone disease, and a formulation thereof. The composition comprising 4-hexylresorcinol (4-HR) as an active ingredient, or an ointment thereof was found to improve bone thickness, density, and strength and control bone remodeling by promoting the differentiation of osteoblasts and suppressing the proliferation and differentiation of osteoclasts in osteoporosis-induced animal models. Thus, the composition or ointment comprising 4-hexylresorcinol (4-HR) as an active ingredient can be provided as a therapeutic agent for bone diseases including bone fracture, osteoarthritis, rheumatoid arthritis, and osteoporosis.

The application discloses a functional composition for improving bone and joint health, a conditioner and application. The functional composition comprises a first active component and a second active component; the first active component comprises elastin peptide, haematococcus pluvialis and ergothioneine; and the second active component comprises one or more of houttuynia cordata and non-denatured type II collagen. The application realizes the protection effect on joint, cartilage and bone health by scientific matching of the components and synergistically improving the glycosaminoglycan level in chondrocytes and the osteocalcin level in osteoblasts. Meanwhile, the components in the functional composition for improving bone and joint health are natural and have good biocompatibility, and have no obvious side effects, so that the application provides a kind of drug or a substitute for the treatment and prevention of bone diseases.

To accurately predict a locomotorium disease in an estimation device, method, and program.SOLUTION: An estimation device includes at least one processor. The processor functions as a learned neural network for deriving an estimation result related to bone density of a bone part from a plain radiation image acquired by executing plain radiography of a subject including the bone part. The learned neural network is learned by using, as teacher data, (i) two radiation images acquired by imaging the subject including the bone part by radioactive rays with different energy distribution, (ii) the radiation image of the subject and a bone image showing the bone part of the subject, or (iii) the radiation image of the subject and a bone density image indicating the bone density of the bone part of the subject, and information related to the bone density of the bone part of the subject.SELECTED DRAWING: Figure 3

Embodiments of the disclosure include methods and compositions related to modulation of bone using particular fibroblasts. The modulation includes reducing osteoclast activity and / or activation and / or stimulating osteoblast activity. In particular cases, bone is modulated in an individual with a bone condition, such as osteoporosis. Particular fibroblasts may be delivered to reduce inflammatory cytokine production including RANK ligand.

FGFR3 gain-of-function mutations are responsible for a family of chondrodysplasias namely, achondroplasia (ACH) the most common form of dwarfism, a lethal form of dwarfism thanatophoric dysplasia (TD) as well as and hypochondroplasia. Recent data demonstrate that Infigratinib (NVP-BGJ398) corrects pathological hallmarks of ACH and support it as a potential therapeutic approach for FGFR3-related skeletal diseases. Now the inventors has investigated the feasibility to treat the defective growth of the skeleton during the pregnancy with the drug. They treated pregnant female Fgfr3Neo / Y367C mice with the drug (4 mg / kg) that was injected subcutaneously at day E14.5 continuing daily through day 1 (after birth). The data indicated that BGJ398 treatment during 5 days in pregnant mice successfully repressed skeletal anomalies that occurred during embryonic stages. Accordingly, the present invention relates to methods for treatment of FGFR3-related skeletal diseases during pregnancy with Infigratinib.

The present invention discloses a long-acting GGG triple-target agonist. The compound of the present invention simultaneously achieves excellent agonist ability at the nM level for the three targets of GLP-1 / GIP / GCGR, and can fully excite the corresponding target organ tissue cells. The compound of the present invention can promote insulin secretion and lower blood sugar; it can also inhibit food intake, delay gastric emptying, increase energy consumption, and ultimately observe a weight loss effect. The compound of the present invention can reduce pancreatic β-cell apoptosis, increase the number of pancreatic β-cells, and improve pancreatic cell function. The compound of the present invention can also improve blood lipids, reduce liver fat accumulation, and inhibit the development of liver inflammation. The compound or composition of the present invention can be used to prevent and / or treat metabolic disorders and related complications. The compound or composition of the present invention can be used to treat bone diseases related to endocrine diseases, metabolic disorders, kidney disease, etc., such as osteoporosis and osteoarthritis.

To provide a novel Lactobacillus paracasei strain with bone regeneration effects, and pharmaceutical and food compositions containing the same. [Solution] The present invention relates to a novel Lactobacillus paracasei L-30 and its uses, and more particularly to Lactobacillus paracasei L-30 (KCTC16035BP) which has the ability to promote the differentiation or formation of osteoblasts, the ability to suppress the differentiation or formation of osteoclasts, and the ability to promote immune activity, and which can regenerate bone, and to a pharmaceutical composition for the treatment or prevention of bone diseases containing the same.

The invention discloses a functional composition capable of improving bone and joint health, a conditioner and application. The functional composition comprises a first active component and a second active component, the first active component is prepared from elastin peptide, haematococcus pluvialis and ergothioneine; the second active component is prepared from one or more of herba houttuyniae and non-denatured type II collagen. Through scientific compatibility of all the components, the levels of glycosaminoglycan in chondrocytes and osteocalcin in osteoblasts are synergistically improved, and the protection effect on joint, cartilage and skeleton health is achieved. Meanwhile, a plurality of components in the functional composition capable of improving the health of the bones and the joints are natural in source, good in biocompatibility and free of obvious side effects, and a medicine or an alternative scheme thereof is provided for treatment and prevention of the bone diseases.

The present invention relates to a composition for the prevention, improvement, or treatment of bone diseases comprising a complex extract composed of deer antler, white soybean, Angelica gigas, and Cnidium officinale as an active ingredient. The complex extract has the effect of promoting the differentiation of bone-forming osteoblasts and bone formation, and promoting the differentiation of bone-resorbing osteoclasts and inhibiting bone resorption at an in vitro level. Furthermore, since it promotes fracture union in a fracture-induced animal model and exhibits a significant recovery effect on fractures, it can be usefully utilized as a health functional food or pharmaceutical related to bone diseases.

To provide osteoblasts and compositions comprising the osteoblasts for treating bone diseases.SOLUTION: Disclosed is an osteoblast having both proliferation ability and differentiation ability, where the osteoblast has higher expression levels of connexin 43, RUNX2 and collagen type 1A compared with those of undifferentiated stem cells and mature osteocytes; higher expression levels of angiopoietin and alkaline phosphatase compared with those of undifferentiated stem cells; and lower expression levels of osterix, osteocalcin and osteopontin compared with those of mature osteocytes. Also, the osteoblast has a lower Ki-67 expression level compared with that of undifferentiated stem cells.SELECTED DRAWING: Figure 1

Provided herein are compounds that are useful for or methods of inhibiting β-catenin or disrupting the interaction between β-catenin and T-cell factor 4, which are useful in the treatment of diseases or health conditions, such as cancer, neurodegenerative, a metabolic disease, a cardiovascular disease, fibrosis, and a bone disease. In one aspect, the compounds have Formula 1 wherein R1 is —(CR42)mXR5; R2 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, aralkyl, heteroaralkyl, or heteroaryl; and R3 is —(CR62)nR7.

The present invention introduces a smart device for dental professionals and surgeons, with flexible mainframes, wheel stands, and electrical components. Its primary goal is to reduce musculoskeletal disorders and improve physical well-being. The device uses intelligent systems and motion tracking to diagnose ergonomic issues during dental procedures, offering personalized digital physiotherapy recommendations. It detects and alerts users about incorrect body postures and environmental conditions through sensors, reducing strain and enhancing comfort. A user-friendly mobile app complements the device, providing login access, AI integration, body angle visualization, real-time results, and comprehensive reports. This invention aims to promote posture awareness, advocate ergonomic best practices, and enhance the physical and environmental health of dental professionals worldwide.

The present invention relates to a composition for inducing differentiation of cranial neural crest stem cells into perivascular cells, a method for producing perivascular cells from cranial neural crest stem cells, and a cell therapeutic agent composition for preventing or treating brain nervous system diseases using the perivascular cells or bone diseases using the cranial neural crest stem cells. The composition and method for inducing differentiation of cranial neural crest stem cells into perivascular cells according to an aspect of the present invention enable the specific production of from cranial neural crest stem cells. In addition, the perivascular cells can be used as a cell therapeutic agent for brain nervous system diseases and using the cranial neural crest stem cells can be used as a cell therapeutic agent for bone diseases.

One aspect relates to a composition for preventing or treating degenerative brain diseases comprising induced pluripotent stem cell-derived mitochondria. According to one aspect, the mitochondria derived from induced pluripotent stem cells were confirmed to exhibit excellent effects in removing reactive oxygen species and in reducing expression of inflammatory cytokines, thereby providing anti-inflammatory effects superior to those of mitochondria derived from other cells. When the mitochondria are treated to damaged nerve cells, recovery and regeneration effects can be confirmed on nerve cells, and as a result of administering the mitochondria to elderly mice, it was also confirmed that the mitochondria have an anti-aging effect. Accordingly, the pharmaceutical composition comprising induced pluripotent stem cell-derived mitochondria according to one aspect of the present invention can be applied in various fields for the prevention or treatment of degenerative brain diseases, particularly bone diseases caused by aging or beta amyloid aggregation.

A method for pre-disease characterization of a patient's anatomical structure includes obtaining a first point cloud representing a diseased state of the patient's bone, generating information indicating at least one of a pathological part of the first point cloud or a non-pathological part of the first point cloud, wherein the pathological part of the first point cloud corresponds to the pathological part of the diseased state of the bone and the non-pathological part of the first point cloud corresponds to the non-pathological part of the diseased state of the bone, generating a second point cloud that includes points corresponding to the non-pathological part but does not include points corresponding to the pathological part, generating a third point cloud representing a pre-disease state of the bone based on the second point cloud, and outputting information indicating the third point cloud representing the pre-disease state of the bone.

The aqueous pharmaceutical formulation with improved stability comprises denosumab and a poloxamer, and preferably a histidine buffer and / or a sugar or sugar alcohol. The formulation is for use in the treatment or prevention of skeletal-related events associated with osteoporosis, reduced bone mass, multiple myeloma, solid tumor bone metastasis, giant cell tumor of bone, or hypercalcemia.

Systems, devices and methods for controlled intramedullary delivery of light (frequencies from about 380 nm to about 500 nm) to treat tissue or bones disorders, including osteomyelitis, by a flexible fiber are provided, where the light is delivered in a circumferential fashion around the fiber, and where the energy delivered from the fiber is of a similar average intensity at the front end and back end of the fiber, and in between. The methods and systems deliver intramedullary light to the canal over long lengths via a minimally invasive pathway to a bone. The methods and systems deliver and maintain a light delivery system within the canal of the bone to provide single or multiple doses of light to kill, eliminate, remove or reduce bacteria, viruses, fungus and pathogens, without removal of the light fiber system, thereby providing single or multiple treatments.

One aspect relates to a composition for preventing or treating degenerative brain diseases comprising induced pluripotent stem cell-derived mitochondria. According to one aspect, the mitochondria derived from induced pluripotent stem cells were confirmed to exhibit excellent effects in removing reactive oxygen species and in reducing expression of inflammatory cytokines, thereby providing anti-inflammatory effects superior to those of mitochondria derived from other cells. When the mitochondria are treated to damaged nerve cells, recovery and regeneration effects can be confirmed on nerve cells, and as a result of administering the mitochondria to elderly mice, it was also confirmed that the mitochondria have an anti-aging effect. Accordingly, the pharmaceutical composition comprising induced pluripotent stem cell-derived mitochondria according to one aspect of the present invention can be applied in various fields for the prevention or treatment of degenerative brain diseases, particularly bone diseases caused by aging or beta amyloid aggregation.

The invention relates to a method for enhancing the osteogenic differentiation of mesenchymal stromal cells (MSCs) by culturing same in an osteogenic medium with an added EphB3-receptor blocking reagent. The blocking reagent may be selected from polyclonal antibodies, monoclonal antibodies, fusion proteins or a combination thereof. The invention also relates to the cells of the osteogenic lineage obtained using the described method and to the EphB3-receptor blocking reagents, for use in the treatment of bone diseases causing bony tissue deficiency and / or bone fractures. The invention also relates to pharmaceutical compositions containing the cells of the osteogenic lineage obtained using the method and / or the EphB3-receptor blocking reagents.

A Lactobacillus paracasei L-30 strain deposited under Accession Number KCTC16035BP has ability to promote osteoblast differentiation or formation, inhibiting osteoclast differentiation or formation, and enhancing immune activity, thereby enabling bone regeneration. A pharmaceutical composition including the Lactobacillus paracasei L-30 strain, a lysate thereof, a culture thereof, an extract thereof, and / or a fraction of the extract may be used for treating or preventing bone diseases.

The application discloses a functional composition, a conditioner and a use for treating or preventing bone and joint diseases. The composition of the functional composition comprises a first active component and a second active component, wherein the first active component comprises elastin peptide 1-500 mu g / mL, haematococcus pluvialis 40-20 mu g / mL, phyllanthus emblica 8-4 mu g / mL and mussel 1-500 mu g / mL in terms of concentration in the functional composition; and the second active component comprises broccoli water extract and / or boric acid substances. The application realizes the synergistic improvement of glycosaminoglycan and osteocalcin levels by scientific compounding, plays a protective role on joint, cartilage and bone health, and has natural, safe, good biocompatibility and no obvious side effects, and provides a kind of drug or a replacement scheme for bone disease treatment and prevention.

The invention discloses application of a recombinant protein CXCL12 in preparation of a medicine for treating AD-HIES related bone diseases, the bone diseases comprise AD-HIES related slight traumatic fracture, recurrent fracture and fracture healing disorder, the medicine takes the recombinant protein CXCL12 as an active ingredient, and the invention further provides a medicine composition for treating the AD-HIES related bone diseases. Experiments prove that the recombinant protein CXCL12 can be used for effectively treating AD-HIES related fracture healing disorders, promoting fracture healing, shortening fracture healing time, providing a potential treatment thought for treating AD-HIES related bone complications, and having a wide application prospect in treatment of AD-HIES related bone complications. Particularly, in the aspect of treatment of bone diseases such as slight traumatic fracture, recurrent fracture and fracture healing disorder in a bone system of an AD-HIES patient.

The invention relates to a liquid pharmaceutical composition comprising an antibody or antigen-binding fragment thereof, cyclodextrin and methionine. Furthermore, it relates to a method of reducing the precipitation of an antibody or antigen-binding fragment thereof in a liquid pharmaceutical composition by adding methionine and cyclodextrin. Specifically. the liquid pharmaceutical composition comprises an anti-sclerostin antibody, hydroxypropyl-γ-cyclodextrin and methionine and can be used in the treatment of a bone disorder associated with at least one of the following: low bone formation, low bone density, low bone mineral content, low bone mass. low bone quality and low bone strength, and especially in the treatment of osteoporosis.Furthermore, the invention relates to a method of reducing injection site inflammation in a mammalian subject comprising administering a therapeutically effective amount of a liquid pharmaceutical formulation comprising an antibody or antigen-binding fragment thereof, cyclodextrin and methionine.

Various embodiments of the present invention are directed to the field of treating and preventing osteoporosis, with particular embodiments directed to a method of ameliorating, treating, or preventing osteoporosis in a human subject employing tomatidine, xylitol, rapamycin, etc., as well as modifying an individual's microbiome to reduce the likelihood of osteoporosis.

Methods and materials for treating skeletal disorders are provided herein. For example, methods and materials for using a dual guanylate cyclase A and B activator (e.g., a polypeptide having the sequence set forth in SEQ ID NO:1) as a therapeutic agent for the treatment of skeletal disorders (e.g., achondroplasia) are provided herein.

Disclosed are methods and compositions for restoring Cyr61 in bone tissue. In certain aspects, the compositions comprise a recombinant Cyr61 carried in carbon nanotubes. The compositions may be used for various methods including restoring Cyr61 expression in bone, increasing bone density, or treating a bone disease in a patient.

The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.

The invention belongs to the field of artificial intelligence, and provides a skeleton microstructure change real-time tracking decision management system, which comprises an image data access module, a dynamic structure analysis unit and an interactive decision output module, the image data access module is used for receiving skeleton three-dimensional time sequence data streams from the high-resolution microscopic imaging equipment and the clinical imaging equipment in real time; the dynamic structure analysis unit comprises a bone microstructure evolution identification module, a mechanical property prediction module and an intervention strategy generation module. Through cooperative work of the image data access module, the dynamic structure analysis unit and the interactive decision output module, full-chain closed-loop management from microstructure perception and mechanical property deduction to intelligent intervention decision is realized, and the ability of early warning and accurate intervention of skeleton diseases is significantly improved.